M. Irving

Discipline

Histoire, Philosophie et Sociologie des sciences (2) Psychologie (1) Sciences de l'information et de la communication (1)

Type de document

Articles (28) Recensions (9)

Co-auteur

Date

Source

Mot-clé

Tumors (17) T cells (17) Cells (17) Tumors (16) Immunotherapy (13) Immunotherapy (13) cancer (11) Cancer (11) Cancer (11) Treatment (10) Human beings (10) immunité (9) Control (9) Mice (9) Immunity (9) Receptors (9) puits (8) automobile (8) Therapeutics (8) Animals (8) thérapie (7) ingéniérie (6) Patients (6) Lymphocytes (6) Engineering (6) Patients (6) plomb (5) infiltration (5) abords (agglomération) (5) Development (5)

Documents écrit par M. Irving (28) | parle de M. Irving (0)

Combining SiRPα decoy-coengineered T cells and antibodies augments macrophage-mediated phagocytosis of tumor cells.
E. Stefanidis et al. (23 avr. 2024)
Coengineering specificity, safety, and function into T cells for cancer immunotherapy.
GMP Giordano Attianese et al.
Activation of the transcription factor NFAT5 in the tumor microenvironment enforces CD8+ T cell exhaustion.
L. Tillé et al.
A lentiviral vector for the production of T cells with an inducible transgene and a constitutively expressed tumour-targeting receptor.
P. Reichenbach et al.
Neoantigen-specific CD8 T cells with high structural avidity preferentially reside in and eliminate tumors.
J. Schmidt et al. (6 juin 2023)
Orthogonal cytokine engineering enables novel synthetic effector states escaping canonical exhaustion in tumor-rejecting CD8+ T cells.
S.J. Carmona et al.
TCR sequencing and cloning methods for repertoire analysis and isolation of tumor-reactive TCRs.
R. Genolet et al. (24 avr. 2023)
Structure-based optimization of type III indoleamine 2,3-dioxygenase 1 (IDO1) inhibitors.
U.F. Röhrig et al.
Sensitive identification of neoantigens and cognate TCRs in human solid tumors.
M. Arnaud et al.
A cell-based phenotypic library selection and screening approach for the de novo discovery of novel functional chimeric antigen receptors.
J.K. Fierle et al. (21 janv. 2022)
Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy.
F.G. Herrera et al.
Choosing the Right Tool for Genetic Engineering: Clinical Lessons from Chimeric Antigen Receptor-T Cells.
M. Irving et al.
Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING.
M. Bruand et al. (20 juil. 2021)
Azole-Based Indoleamine 2,3-Dioxygenase 1 (IDO1) Inhibitors.
U.F. Röhrig et al. (25 févr. 2021)
Optimized gene engineering of murine CAR-T cells reveals the beneficial effects of IL-15 coexpression.
E. Lanitis et al. (1 févr. 2021)
High versus low dose irradiation for tumor immune reprogramming.
M.O. de Olza et al.
Preclinical Evaluation and Dosimetry of [111In]CHX-DTPA-scFv78-Fc Targeting Endosialin/Tumor Endothelial Marker 1 (TEM1).
F. Cicone et al.
miR-155 Overexpression in OT-1 CD8+ T Cells Improves Anti-Tumor Activity against Low-Affinity Tumor Antigen.
G.C. Monnot et al. (27 mars 2020)
Rational combinations of immunotherapy with radiotherapy in ovarian cancer.
F.G. Herrera et al.
Safety and Tolerability of Adoptive Cell Therapy in Cancer.
B. Wolf et al.
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function.
S. Vigano et al. (2019)
Consensus guidelines for the use and interpretation of angiogenesis assays.
K. Alitalo et al.
CART cells are prone to Fas- and DR5-mediated cell death.
B.O. Tschumi et al. (13 juil. 2018)
Correction to: CART cells are prone to Fas- and DR5-mediated cell death.
B.O. Tschumi et al. (2018)
Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.
M. Irving et al. (2017)

next